Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. scaut

SCAUT SIGNED

Ser-Col; from finger to laboratory; personalized and automated serum collection for laboratory diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SCAUT project word cloud

Explore the words cloud of the SCAUT project. It provides you a very rough idea of what is the project "SCAUT" about.

incredibly    18    diagnostic    performance    months    finger    incineration    wasteful    engage    innovative    full    stable    reg    breaking    serum    investors    analytical    collection    realize    safe    trained    burden    obtain    reducing    col    industry    standards    compatibility    50    simplifies    manufacturing    stick    barriers    few    sampling    diagnostics    professionals    clinical    commercialization    environment    painless    healthcare    ready    social    blood    drops    collected    adoption    venipuncture    accelerate    groups    tube    cumulative    cold    waste    disposed    prior    laboratory    taxing    finalize    ultimately    separation    version    decentralization    logistic    2023    validate    disease    specimens    biohazardous    clinically    replacing    813    laboratories    centralized    standardized    optimal    2027    vulnerable    million    reduces    device    validation    created    95    platform    profit    urgent    centrifuge    storage    links    463    scaut    population    combines    market    infectious    automated    ser    thereby    attract    diseases   

Project "SCAUT" data sheet

The following table provides information about the project.

Coordinator		 LABONOVUM BV 

Organization address
address: ZIJAKKERTJE 2
city: LIMMEN
postcode: 1906 BE
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website http://www.scaut.info
 Total cost 3˙984˙850 €
 EC max contribution 2˙998˙374 € (75%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LABONOVUM BV NL (LIMMEN) coordinator 761˙687.00
2    BLOK SYSTEM SUPPLY BV NL (AMSTERDAM) participant 1˙540˙087.00
3    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 453˙875.00
4    YEREVAN STATE MEDICAL UNIVERSITY AFTER MKHITAR HERATSI AM (YEREVAN) participant 242˙725.00

Map

 Project objective

95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incineration, which is incredibly wasteful and taxing on our environment. In Europe, there is an urgent need for innovative approaches that engage vulnerable groups and increase access to infectious disease testing by breaking-down social and logistic barriers to healthcare. The decentralization of healthcare have created a need for a simple, safe, standardized and painless collection of serum specimens. The Ser-Col® is a novel serum separation device that simplifies and combines both blood collection and serum separation. With a few drops of blood from a finger stick, serum can be collected which is stable for several months prior to analysis of clinically relevant serum parameters, and thereby reducing biohazardous waste production by 50%. Ser-Col simplifies and reduces the cost of serum sampling by replacing the blood tube, trained personnel, cold storage, and centrifuge with a reliable and easy to use device that links target population to centralized diagnostics laboratories, ultimately leading to the long-term reduction of the burden of infectious diseases. The SCAUT consortium will scale up manufacturing to deliver a market ready version of the Ser-Col and validate its clinical performance against existing standards. To ensure market uptake the consortium will develop an automated serum processing platform for optimal compatibility with exciting laboratory diagnostic equipment and facilitate adoption of Ser-Col by healthcare professionals. This will accelerate commercialization, attract investors and to establish industry partnerships required to realize the full potential of the technology. The SCAUT project seeks to obtain €3 million to finalize the analytical and clinical validation and go-to-market of the Ser-Col® device. The estimated cumulative profit is €463.813 in 2023 increasing towards €18 million in 2027.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-01-30 08:24:10

Take a look to the deliverables list in detail:  detailed list of SCAUT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCAUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCAUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More  

DigiMAT (2019)

Smart solution for connecting process with material characteristics to achieve new generation of digital materials for the automotive industry.

Read More